Pain management in craniofacial pathology is a major clinical challenge. Thorough understanding of the molecular mechanisms underlying craniofacial pain should help the development of novel strategies for better treatment. TRPV1 is a receptor for capsaicin and multiple endogenous stimuli such as heat and proton. In addition to its well-known contribution to thermal hyperalgesia, TRPV1 also integrates nociceptive signaling under inflammation and injury, and is implicated in various craniofacial pathological conditions. Although TRPV1 is a good candidate for craniofacial anti-hyperalgesic therapy, antagonists that suppress TRPV1 function completely may not be applicable due to serious adverse side effects. Therefore, it will be important to develop therapeutics targeting pathology-specific TRPV1 activity. Based on the literature and our preliminary data, we hypothesize that alteration in activity of TRPV1 mediated by post-translational modification and genetic variations contributes to craniofacial pathological pain. To test this hypothesis, we will perform a comprehensive analysis in vitro, in vivo and in humans. We will determine modality-specific basis for the phosphorylation-induced hypersensitivity of TRPV1 (Aim 1), examine the contribution of PKC-induced phosphorylation of TRPV1 to hypersensitivity in sensory neurons and to craniofacial pain in vivo (Aim 2), and determine whether nonsynonymous variations within the human TRPV1 locus induce coupled alterations of channel functions in vitro and craniofacial pain phenotypes in humans (Aim 3). If successful, this project will provide information that guides development of novel approaches for targeting pathology-specific residues of TRPV1 and/or selective patient subgroups for treating craniofacial pain.
The goal of this project is to elucidate how pain receptor TRPV1 contributes to pain under physiological and pathological conditions. This is an important step for the development of novel therapeutics targeting the pain receptor TRPV1 more specifically with fewer side effects for suppressing pathological pain.
|Wang, Sheng; Brigoli, Benjamin; Lim, Jongseuk et al. (2018) Roles of TRPV1 and TRPA1 in Spontaneous Pain from Inflamed Masseter Muscle. Neuroscience 384:290-299|
|Hall, Bradford E; Prochazkova, Michaela; Sapio, Matthew R et al. (2018) Phosphorylation of the Transient Receptor Potential Ankyrin 1 by Cyclin-dependent Kinase 5 affects Chemo-nociception. Sci Rep 8:1177|
|Wang, Sheng; Lim, Jongseuk; Joseph, John et al. (2017) Spontaneous and Bite-Evoked Muscle Pain Are Mediated by a Common Nociceptive Pathway With Differential Contribution by TRPV1. J Pain 18:1333-1345|
|Wang, Sheng; Wang, Sen; Asgar, Jamila et al. (2017) Ca2+ and calpain mediate capsaicin-induced ablation of axonal terminals expressing transient receptor potential vanilloid 1. J Biol Chem 292:8291-8303|
|Lee, Ki Seok; Zhang, Youping; Asgar, Jamila et al. (2016) Androgen receptor transcriptionally regulates ?-opioid receptor expression in rat trigeminal ganglia. Neuroscience 331:52-61|
|Chung, Man-Kyo; Park, Jennifer; Asgar, Jamila et al. (2016) Transcriptome analysis of trigeminal ganglia following masseter muscle inflammation in rats. Mol Pain 12:|
|Chung, Man-Kyo; Campbell, James N (2016) Use of Capsaicin to Treat Pain: Mechanistic and Therapeutic Considerations. Pharmaceuticals (Basel) 9:|
|Wang, Sen; Joseph, John; Diatchenko, Luda et al. (2016) Agonist-dependence of functional properties for common nonsynonymous variants of human transient receptor potential vanilloid 1. Pain 157:1515-24|
|Wang, Sen; Joseph, John; Ro, Jin Y et al. (2015) Modality-specific mechanisms of protein kinase C-induced hypersensitivity of TRPV1: S800 is a polymodal sensitization site. Pain 156:931-41|
|Chung, Man-Kyo; Lee, Jongseok; Joseph, John et al. (2015) Peripheral group I metabotropic glutamate receptor activation leads to muscle mechanical hyperalgesia through TRPV1 phosphorylation in the rat. J Pain 16:67-76|
Showing the most recent 10 out of 13 publications